Pluristem Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics

PSTI 8.720

+0.2%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: FJB	4/11/2013 8:16:02 AM
	1 Recommendation of 295

3:19AM Pluristem Therapeutics: United Therapeutics receives regulatory approval to commence Phase I study of Pluristem's PLX-PAD cells for pulmonary arterial hypertension ( PSTI) 3.02 : Co announces that following favorable preclinical studies, United Therapeutics (UTHR) received approval to perform a human Phase I study in Australia using PSTI's PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. On June 20, 2011 UTHR and Pluristem entered into a licensing agreement pursuant to which UTHR will develop, market and sell PSTI's PLX-PAD cells for PAH.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next